Idiopathic Intracranial Hypertension

Idiopathic intracranial hypertension (IIH) is a condition in which the pressure inside the skull—called intracranial pressure (ICP)—rises abnormally without any identifiable cause. There is no brain tumor, blood clot, infection, or other structural problem responsible for the pressure buildup. The word idiopathic means “of unknown cause.” The elevated pressure pushes on the brain, the optic nerves, and the surrounding structures, producing a characteristic set of symptoms, most commonly severe headaches and visual disturbances. IIH is also known historically as pseudotumor cerebri—a term coined because it mimics the symptoms of a brain tumor without one being present—and older literature may refer to it as benign intracranial hypertension, though this term is now discouraged because IIH can cause permanent vision loss and is far from benign in its impact.

Idiopathic intracranial hypertension is not a rare condition, and its frequency is rising. In the United States, incidence has increased dramatically over recent decades, tracking closely with rising obesity rates. The condition predominantly affects women of reproductive age who are overweight or obese, though it can occur in men, children, and older adults. With early diagnosis and appropriate treatment, most people with IIH can protect their vision and manage symptoms effectively. However, left untreated or undertreated, the elevated pressure can permanently damage the optic nerves and cause lasting vision loss. Chronic, disabling daily headaches—even in people whose vision is well protected—is one of the most impactful aspects of living with this condition.

Idiopathic intracranial hypertension is a chronic, often recurrent condition that requires active, ongoing management rather than a one-time treatment. In some patients, sustained weight loss leads to full remission. In others, long-term medication or even surgical procedures are needed to keep intracranial pressure under control. Because IIH primarily affects young women during their working and reproductive years, its effects on daily function, employment, mental health, and quality of life are significant and deserve comprehensive, individualized care. Montefiore Einstein researchers have contributed foundational work to understanding the epidemiology of IIH, including one of the largest U.S. population studies of the condition to date.

Doctors classify IIH based on the pattern of presentation—particularly whether the optic discs are swollen—and the pace at which symptoms develop. The following recognized forms guide both diagnosis and treatment decisions.

• IIH with papilledema: the classic and most common form. Papilledema means swelling of the optic disc—the visible head of the optic nerve, seen during an eye examination when the doctor looks into the back of the eye. This swelling occurs because the elevated cerebrospinal fluid (CSF) pressure surrounding the optic nerve is transmitted into the nerve sheath, causing the nerve head to bulge. This form carries the greatest risk of permanent vision loss and fully meets the established diagnostic criteria for IIH.
• IIH without papilledema: Some patients have all the other features of IIH—elevated CSF pressure and characteristic symptoms such as headache and pulsatile tinnitus—but no visible optic disc swelling. This form does not directly threaten vision through disc compression, but it still causes significant headache disability. Diagnosis requires additional supporting features and careful evaluation to make sure another cause of headache is not being overlooked.
• Fulminant IIH: a rare and severe form affecting fewer than 5% of IIH patients, in which dramatic vision loss develops within four weeks of symptom onset. Approximately half of patients with fulminant IIH are left with legally blind vision in both eyes despite aggressive treatment. This form is a neuro-ophthalmic emergency requiring urgent surgical intervention.
• Pediatric IIH: IIH in children has a distinct profile. In infants and toddlers under age 3, it affects boys and girls almost equally and presents differently from adults—with a bulging fontanelle (the soft spot on a baby’s head), irritability, vomiting, and sometimes fever. Papilledema is less common in young children. Medications and infections are the most frequent triggers in this age group. Most young children recover with conservative treatment.

By definition, the specific underlying cause of IIH is unknown. However, research has identified several interconnected mechanisms that appear to drive the abnormal rise in intracranial pressure. The most widely accepted explanation centers on an imbalance between how much CSF is produced in the brain and how efficiently it drains away. CSF is a clear fluid produced by a specialized structure in the brain called the choroid plexus. It circulates around the brain and spinal cord and is normally reabsorbed at a rate that keeps intracranial pressure stable. In IIH, this balance is disrupted—either because too much CSF is produced, too little is reabsorbed, or venous blood pressure inside the skull is elevated, which impairs CSF drainage.

Obesity—particularly the accumulation of fat around the abdomen—appears to drive several of these mechanisms simultaneously. Abdominal fat raises systemic venous pressure, which backs up into the blood vessels draining the brain and raises intracranial pressure. Excess fat tissue also produces higher-than-normal levels of androgens (male hormones present in both men and women), which stimulate the choroid plexus to produce more CSF. Research from Montefiore Einstein and other institutions has identified that an enzyme called 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-HSD1), which is more active in the fat tissue and choroid plexus of people with IIH, further amplifies CSF production. The majority of patients with IIH also have a narrowing in one or both of the large veins that drain blood from the brain—called transverse sinus stenosis—which impairs fluid outflow and raises intracranial pressure further. Several additional factors are associated with triggering elevated intracranial pressure in susceptible individuals:

• Obesity and recent weight gain: by far the most important contributing factor. A weight gain of as little as 5–15% of body weight can trigger IIH in a susceptible person. The mechanism involves increased venous pressure, androgen excess from fat tissue, and hormonal changes that directly affect CSF production.
• Hormonal factors: IIH overwhelmingly affects women of reproductive age, implicating sex hormones. Polycystic ovary syndrome (PCOS)—a condition associated with androgen excess—is significantly more common in women with IIH than in the general population. IIH has also been reported in transgender women after starting estrogen therapy.
• Certain medications: Some drugs are known to trigger elevated intracranial pressure as a side effect. These include tetracycline-class antibiotics (such as minocycline and doxycycline, commonly used for acne), vitamin A and retinoid medications (including isotretinoin/Accutane®), corticosteroid withdrawal (stopping steroids too quickly), exogenous growth hormone, and lithium. These cases are technically classified as secondary intracranial hypertension—not true IIH—but must be considered during the diagnostic evaluation.
• Obstructive sleep apnea: Intermittent drops in oxygen during sleep raise intracranial pressure and are both a risk factor for and a potential secondary cause of elevated ICP.
• Other systemic conditions: Severe anemia, adrenal insufficiency, systemic lupus erythematosus, and renal failure have been associated with elevated intracranial pressure that mimics IIH.

Idiopathic intracranial hypertension can occur in people without any of the typical risk factors, but the following characteristics significantly raise the likelihood of developing the condition.

• Obesity and overweight: the single most important risk factor. More than 90% of adults with IIH are overweight or obese. With every 10 kg/m2 increase in body mass index (BMI), the odds of severe visual loss from IIH increase by 1.4 times.
• Female sex: Women are over three times more likely than men to develop IIH. This ratio has been widening in recent decades as obesity rates rise. The female predominance is linked to hormonal differences, including androgen levels and estrogenic states.
• Reproductive age: IIH most commonly presents in women between the ages of 15 and 45. This is the peak period of hormonal activity and is also the period of highest obesity prevalence in the affected demographic.
• Recent weight gain: Even modest weight gain in a short time can trigger IIH in a susceptible person. Weight gain is also a common trigger for relapse after a period of remission.
• Polycystic ovary syndrome (PCOS): PCOS is one of the most common health conditions seen alongside IIH, likely because both are linked to androgen excess. Women with PCOS should be aware of IIH risk, particularly if they are also overweight.
• Hyperlipidemia and metabolic syndrome: —Elevated cholesterol and triglycerides and other features of metabolic syndrome are among the most common medical conditions found in people with IIH.
• Obstructive sleep apnea: This is both a contributing cause and a common companion condition in IIH patients.
• Socioeconomic deprivation: Studies have found that IIH is more common in populations facing greater socioeconomic disadvantage, likely reflecting higher rates of obesity and reduced access to preventative healthcare.
• Geographic location: In the United States, IIH is most prevalent in the South, which also has among the highest regional rates of obesity.
• Certain medications: Tetracycline antibiotics, isotretinoin, and corticosteroid withdrawal are recognized triggers, particularly in adolescents treated for acne.

There is no population-wide screening program for IIH. The condition is identified when a person at risk—most often a young woman with obesity who develops persistent new headache, visual disturbances, or a whooshing sound in the ears—seeks medical evaluation, or when a doctor detects swollen optic discs during a routine eye exam. Any woman of reproductive age with obesity who develops a new, persistent, or worsening headache should mention it to her doctor and ask whether an eye examination to look for papilledema is appropriate. Parents of overweight teenagers who are being treated with tetracycline antibiotics or isotretinoin for acne should also be aware of IIH symptoms and report headache or visual changes promptly.

Idiopathic intracranial hypertension in its idiopathic form cannot be entirely prevented. However, because obesity and weight gain are so strongly linked to the condition, maintaining a healthy body weight is the most powerful preventative step available. The following strategies can reduce risk or support early detection:

• Maintain a healthy body weight: Because weight gain—even a modest 5–15% of baseline body weight—can trigger IIH, avoiding significant weight gain over time is the most evidence-based preventative strategy. Weight loss of 10% or more of body weight is associated with complete IIH remission in many patients.
• Be aware of medication risks: Patients prescribed tetracyclines (particularly for acne), isotretinoin, or corticosteroids should be informed of the IIH risk. Steroids should never be stopped abruptly without a doctor’s guidance. New headache or visual changes during any of these treatments should be reported immediately.
• Avoid excessive vitamin A supplementation: Hypervitaminosis A—taking far more vitamin A than the body needs—can raise intracranial pressure. Vitamin A supplements should not be taken in excess of recommended daily allowances without medical supervision.
• Treat obstructive sleep apnea: Using continuous positive airway pressure (CPAP) therapy consistently for sleep apnea may help reduce intracranial pressure in patients who have both conditions.
• Seek early evaluation for concerning symptoms: Because fulminant IIH can cause irreversible blindness very rapidly, anyone with a new headache and even mild blurring of vision should be evaluated promptly rather than waiting. Early referral to neurology or neuro-ophthalmology is critical when papilledema is found on examination.

The hallmark symptom of IIH is a persistent, often severe headache combined with visual disturbances caused by elevated pressure pushing on the brain and optic nerves. Headache is reported in 75–94% of IIH patients and is typically the symptom that drives people to seek care. It often has a migrainous quality—throbbing, one-sided, associated with nausea—or may be a constant daily pressure-like pain. It is frequently worse in the morning and worsens when lying flat. The combination of daily headache and a distinctive whooshing or pulsing sound heard in the ears is particularly characteristic of IIH and should always prompt evaluation.

Signs and symptoms of idiopathic intracranial hypertension include:

• Persistent headache: the most common symptom, present in about 84% of patients. The headache is often daily, severe, and described as throbbing or pressure-like. It tends to be worse in the morning, when lying flat, or with activities that raise intracranial pressure, such as coughing or straining.
• Transient visual obscurations: brief episodes—lasting only seconds—in which vision dims, grays out, or goes dark in one or both eyes. These episodes are triggered by postural changes or head movement and are caused by momentary disruption of blood flow to the swollen optic nerve heads. They are present in about 68% of IIH patients.
• Pulsatile tinnitus: a rhythmic whooshing, marching, or heartbeat-like sound heard in one or both ears, synchronized with the heartbeat. This is a highly characteristic symptom of IIH, present in 52–60% of patients. It is caused by turbulent flow in the intracranial venous sinuses and often disappears with successful treatment.
• Light sensitivity (photophobia): This is discomfort or pain in bright light, affecting 42–73% of patients.
• Dizziness: This is present in approximately 52% of patients.
• Back and neck pain: This is caused by elevated CSF pressure along the spine; back pain is reported in about 53% and neck pain in about 42% of IIH patients.
• Visual blurring or dimming: reported by about 32% of patients as a subjective symptom. In people with papilledema, formal visual field testing reveals peripheral field loss in the majority, though central vision is usually preserved until advanced disease.
• Double vision (diplopia): horizontal double vision caused by pressure-related weakness of the sixth cranial nerve (the nerve that controls outward eye movement). This palsy is a known sign of elevated intracranial pressure from any cause and is present in about 18% of IIH patients.
• Cognitive difficulties: Brain fog, difficulty concentrating, and memory problems are reported by about 20% of patients and can be among the most limiting symptoms for work and daily function.
• Papilledema on examination: swelling of the optic disc, visible to a doctor during an eye examination. This is the hallmark physical sign of IIH with papilledema, present in about 96% of patients with the classic form. It is caused by elevated pressure being transmitted into the sheath surrounding the optic nerve.

Idiopathic intracranial hypertension is diagnosed by a neurologist or neuro-ophthalmologist—a specialist in the connections between the nervous system and vision. Because IIH must be distinguished from other conditions that raise intracranial pressure—including brain tumors, blood clots in the veins of the brain, and medication side effects—diagnosis requires ruling out all secondary causes before confirming the idiopathic form. The diagnostic process typically involves imaging of the brain, measurement of the CSF pressure through a lumbar puncture, and detailed evaluation of the optic nerves and visual fields.

The established diagnostic standard requires all of the following to be met: symptoms consistent with elevated intracranial pressure; CSF pressure of 250 mm H2O or higher in adults (280 mm H2O in children); normal CSF composition; normal brain imaging (with some characteristic findings of IIH allowed); and no secondary cause identified. The specific tests used include:

• Fundoscopy and fundus photography: examination of the optic discs to detect papilledema. This can be performed quickly by an ophthalmologist, neurologist, or emergency physician and is the first and most important step when IIH is suspected. The severity of papilledema is graded on a standardized scale called the Frisen classification (grades 0 through 5).
• Optical coherence tomography (OCT): a noninvasive retinal scan that measures the thickness of the nerve fiber layer around the optic disc. It can detect subtle optic nerve head elevation before papilledema is visible to the naked eye and is used to monitor treatment response over time. A specific OCT measurement called the ganglion cell layer analysis detects irreversible retinal nerve cell loss and signals permanent optic nerve injury—a finding that should prompt urgent escalation of treatment.
• Magnetic resonance imaging (MRI) of the brain with gadolinium contrast: mandatory to exclude brain tumors, hydrocephalus, and other structural causes of elevated pressure. The MRI is typically normal in IIH, but several characteristic supportive findings may be present: flattening of the back of the eyeball (posterior globe flattening), distension of the optic nerve sheath, an empty-appearing sella (the bony saddle where the pituitary gland sits, which becomes flattened by the elevated pressure), and narrowing of the transverse venous sinuses.
• MR venography (MRV) or CT venography (CTV): imaging of the brain’s venous drainage system to exclude venous sinus thrombosis (a blood clot in the brain’s venous sinuses, which cannot be ruled out on a standard MRI alone). These tests also identify transverse sinus stenosis—a narrowing of the main venous drainage channels—which is present in the majority of IIH patients and contributes to elevated pressure.
• Lumbar puncture (spinal tap) with opening pressure measurement: the definitive test for confirming elevated intracranial pressure. A thin needle is inserted between the lumbar vertebrae while the patient lies on their side, and CSF pressure is measured with a manometer. A pressure of 250 mm H2O or higher in adults confirms elevated ICP. The CSF sample is also tested to ensure it is chemically normal—abnormal protein, blood cells, or glucose in the CSF would point to another diagnosis.
• Automated visual field testing (perimetry): a computerized test that maps the full range of vision. The most common finding in IIH is an enlarged blind spot, caused by pressure on the optic nerve head. Progressive peripheral visual field loss indicates worsening optic nerve damage and is a key outcome measure for tracking whether treatment is working.
• Blood tests: ordered to exclude secondary causes: complete blood count (for anemia), serum vitamin A levels, thyroid function, autoimmune markers (antinuclear antibody—ANA, anti-double stranded DNA—anti-dsDNA), cortisol (for adrenal insufficiency), and renal function. Testosterone levels are also checked in women because elevated androgen levels are characteristic of IIH and support the diagnosis.

Idiopathic intracranial hypertension is not curable in most patients, but it is highly treatable. The two overarching goals are to protect vision by reducing the pressure on the optic nerves and to manage headache disability. Treatment is stepped—beginning with the least intensive effective approach and escalating when vision is threatened or symptoms are not adequately controlled. No drug is currently U.S. Food and Drug Administration (FDA)-approved specifically for IIH, but several medicines used in practice have strong evidence supporting their use. For obese patients, weight management is the only intervention with the highest level (class I) of clinical trial evidence as a primary IIH treatment. In the landmark IIH Treatment Trial (IIHTT), weight loss combined with medication significantly outperformed weight loss alone in improving vision and papilledema. A weight loss of 10% or more of baseline body weight is associated with complete remission in many patients. For those who cannot achieve adequate weight loss through diet and exercise, bariatric surgery has been shown to produce significantly better outcomes than community weight management programs, with rates of papilledema 59% lower in the bariatric surgery group at two years.

Acetazolamide (Diamox®) is the first-line medication for IIH. It is a carbonic anhydrase inhibitor that reduces CSF production by suppressing the ion transport system in the choroid plexus. The IIHTT established acetazolamide plus weight loss as the evidence-based standard of care. Doses of up to 4 grams per day are used, titrated up gradually based on response and tolerability. The most common side effects are tingling in the hands and feet (which is very common but usually harmless), an unpleasant metallic taste with carbonated drinks, nausea, and fatigue. Electrolyte imbalances can occur and are monitored with periodic blood tests. For patients who cannot tolerate acetazolamide or who also have migraines—a very common IIH comorbidity—topiramate (Topamax®) is a useful alternative. Topiramate has mild carbonic anhydrase activity, the added benefit of promoting modest weight loss, and is an established migraine preventative, making it particularly suited for IIH patients whose headaches have a migrainous quality. Furosemide (Lasix®), a diuretic, may be added to acetazolamide when medication alone is not providing adequate pressure control. An exciting area of emerging treatment is glucagon-like peptide-1 (GLP-1) receptor agonists—the class of medicines that includes semaglutide (Ozempic®/Wegovy®) and exenatide. A randomized controlled trial called the IIH:Pressure Trial demonstrated that exenatide directly reduced intracranial pressure through a mechanism at the choroid plexus, independent of weight loss. Real-world data on semaglutide show reductions in IIH-related disease activity of approximately 40% at three months. These medicines are not yet FDA-approved specifically for IIH but are being used off-label and are the subject of an ongoing phase 3 clinical trial.

When vision is acutely threatened or medical treatment has failed to protect the optic nerves adequately, procedural or surgical intervention is needed. Three main options are used. Optic nerve sheath fenestration (ONSF) is a surgical procedure in which small incisions are made in the fibrous sheath surrounding the optic nerve just behind the eye, allowing CSF to decompress away from the nerve and directly protecting it from damage. It is the preferred option when vision loss is the primary concern and headache control is secondary. CSF diversion surgery creates a permanent drainage channel to redirect excess CSF out of the skull—the most commonly used approaches in IIH are a lumboperitoneal (LP) shunt, which runs a tube from the spinal fluid space in the lower back to the abdominal cavity, and a ventriculoperitoneal (VP) shunt, which drains from the brain’s fluid-filled ventricles. Shunting is more effective for headache control but carries risks of shunt failure and blockage requiring repeat surgery. Venous sinus stenting is a newer catheter-based procedure in which a metal stent is placed inside the narrowed transverse venous sinus to restore normal blood drainage and reduce intracranial pressure. In carefully selected patients with confirmed venous sinus narrowing, published outcomes show improvement or resolution of headache in about 70%, papilledema in about 85%, and pulsatile tinnitus in nearly 89% of cases. An ongoing randomized trial—the Surgical IIH Treatment Trial (NCT03501966)—is directly comparing medical management, ONSF, and VP shunt to establish which surgical approach is most effective overall.

Idiopathic intracranial hypertension is a chronic condition that varies significantly in its impact from person to person. With early diagnosis and appropriate treatment, many people with IIH protect their vision fully and find ways to manage their headaches and other symptoms over the long term. Some achieve complete remission through sustained weight loss and may eventually be able to stop medication. Others live with IIH as a long-term managed condition, similar to other chronic diseases. Chronic daily headache—present in a substantial proportion of patients—remains one of the most significant quality-of-life challenges even when vision is well controlled. Because IIH primarily affects young women during their working and reproductive years, coordinating care across neurology, neuro-ophthalmology, weight management, endocrinology, and headache medicine specialists gives the best foundation for managing the condition across different life stages. At Montefiore Einstein, whose researchers have contributed foundational epidemiological data on IIH, a multidisciplinary team is available to support patients at every stage of diagnosis and treatment.

To further your understanding of your diagnosis and to contribute to cutting-edge research, consider participating in a clinical trial so clinicians and scientists can learn more about causes, symptoms, treatment, and prevention of idiopathic intracranial hypertension and related disorders. Clinical research uses human volunteers to help researchers learn more about a disorder and perhaps find better ways to safely detect, treat, or prevent disease.

All types of volunteers are needed—those who are healthy or may have an illness or disease—of all different ages, sexes, races, and ethnicities to ensure that study results apply to as many people as possible, and that treatments will be safe and effective for everyone who will use them.

To find active clinical studies on idiopathic intracranial hypertension, visit National Institutes of Health (NIH) Clinical Research Trials and You and ClinicalTrials.gov. Active studies include the Surgical IIH Treatment Trial (NCT03501966)—comparing medical management, optic nerve sheath fenestration, and VP shunt surgery—and ongoing phase 3 trials evaluating GLP-1 receptor agonists as a targeted IIH treatment.